Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYBB | P04839 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395107 | 0.92 | MAPT (0.52) | KMT2AMEN1LMNACA12CA1 | |
| SCHEMBL662221 | 0.89 | LMNA (0.64) | KMT2AMEN1LMNAESR1ESR2 | |
| SCHEMBL184993 | 0.81 | CA12 (0.72) | KMT2AMEN1LMNACA12CA1 | |
| SCHEMBL1353392 | 0.80 | KMT2A (0.51) | KMT2AMEN1LMNACA12CA1 | |
| SCHEMBL9125713 | 0.78 | SNCA (0.48) | KMT2AMEN1LMNACA12CA1 | |
| SCHEMBL1356478 | 0.78 | HSD17B2 (0.72) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL17912414 | 0.76 | ESR1 (0.69) | LMNACA12CA1CA2CA7 | |
| SCHEMBL6693656 | 0.75 | KMT2A (0.64) | KMT2AMEN1LMNAMAPTKDM4E | |
| SCHEMBL199239 | 0.75 | CA1 (0.69) | KMT2AMEN1LMNACA12CA1 | |
| SCHEMBL7694628 | 0.74 | KMT2A (0.49) | KMT2AMEN1LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | claimed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | KISS ROBERT (BE) | 2011-11-17 | — | — | US | disclosed |
| EP-2367545-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | Université Libre de Bruxelles (BE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043631-A1 | DI-VANILLOYL AND TRI-VANILLOYL DERIVATIVES FOR USE IN ANTI-CANCER THERAPY | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280940-A1 | Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy | PSEN2, PSEN1, VHL | KMT2A 1383/4885MEN1 2016/4885LMNA 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.